Skin News and Research

RSS

DNA reveals earliest proven case of leprosy, Turin Shroud not from Jesus-era Jerusalem

The DNA of a 1st century shrouded man found in a tomb on the edge of the Old City of Jerusalem has revealed the earliest proven case of leprosy. Details of the research will be published December 16 in the PloS ONE Journal.

16 Dec 2009

StemCells receives U.S. patent for propagation and/or derivation of embryonic stem cells

StemCells, Inc. announced today that it has received a Notice of Allowance and a Notice of Issuance from the U.S. Patent and Trademark Office for two patents claiming technologies for the establishment and maintenance of cell pluripotency (the ability to become any cell in the body, which is the defining attribute of embryonic stem cells), including the reprogramming of cells to create pluripotent stem cells.

16 Dec 2009

MRSA, the most concerning pathogen to surveyed for skin and skin structure infections

Arlington Medical Resources (AMR) and Decision Resources find that methicillin-resistant Staphylococcus aureus (MRSA) is the most concerning pathogen to surveyed European infectious disease specialists with regard to their treatment of skin and skin structure infections.

16 Dec 2009

ProtoKinetix evaluates major European proposals to expand AAGP technology use

ProtoKinetix Inc. (PKTX) has been approached by a European biopharma investment group with a series of proposals to develop commercial partnerships in the pharmaceutical/cosmetic arenas.

16 Dec 2009

Rib-X Pharmaceuticals and MGH enter into collaborative research agreement

Rib-X Pharmaceuticals, Inc., a company focused on the discovery, development and commercialization of novel drugs for the treatment of serious multi-drug-resistant infections announced today it has entered into a collaborative research agreement with Massachusetts General Hospital (MGH).

16 Dec 2009

BioAlliance Pharma SA to enter Phase II clinical trial for clonidine Lauriad and Phase I clinical trial for AMEP

BioAlliance Pharma SA, a company dedicated to the treatment and supportive care of cancer and AIDS patients, today announces the approval from the French Drug Agency (AFFSSaPS) to enter Phase II clinical trial for clonidine Lauriad® in radiotherapy and chemotherapy-induced oral mucositis and the approval from Danish and Slovene Agencies to enter Phase I clinical trial for AMEPTM in invasive melanoma.

15 Dec 2009

FDA grants marketing approval for EnzySurge's new SilverStream solution for prescription use

EnzySurge Ltd. (EnzySurge), a provider of innovative solutions for the advanced chronic wound management market, announced today that it has received clearance from the U.S. Food and Drug Administration (FDA) to market its new SilverStream(TM) solution for prescription use. The FDA also cleared DermaSept, an Over-the-Counter version of the SilverStream product.

15 Dec 2009

Cellular and subcellular effects of PACE technology presented

SANUWAVE Health, Inc., (www.sanuwave.com), an emerging medical technology company focused on the development and commercialization of non-invasive, biological response activating devices in the regenerative medicine area, announced that the cellular and subcellular effects of PACE™ technology were described during a lecture presented this past weekend.

15 Dec 2009

Findings suggest variations in accelerated aging disorders

UT Southwestern Medical Center researchers have provided the most extensive account to date of the unique observable characteristics seen in patients with an extremely rare premature aging syndrome.

15 Dec 2009

PPI announces new Exotec Cubital Tunnel Splint

When staff from a leading orthopaedic group grew tired of struggling to apply the difficult to adjust and uncomfortable cubital tunnel splints available on the market, they enlisted Professional Products, Inc. (PPI) to develop a superior alternative. PPI, a leader and innovator in orthopaedic solutions for nearly five decades, responded with the revolutionary Exotec Cubital Tunnel Splint(TM) (cubitaltunnelsplint.com), which it announced today.

15 Dec 2009

INS cites FDA-approved Totect antidote for anthracycline extravasations

The third edition of Infusion Nursing: An Evidence-Based Approach, published by the Infusion Nurses Society (INS), includes Totect(®), the only FDA-approved treatment for anthracycline extravasation. Anthracyclines are a group of chemotherapy medications including daunorubicin, doxorubicin, idarubicin and epirubicin that have been used in the treatment of various types of cancer since the early 1970s.

15 Dec 2009

Majority of women take natural menopause remedies for safe and effective solutions

When a woman starts going through menopause, her entire life can change without warning. Menopause symptoms can cause undesirable reactions in the body that runs the gamut from hot flashes and weight gain to mood swings, sleeplessness and irritability.

15 Dec 2009

Health experts discuss new treatment strategies for lung cancer at AACR-IASLC Joint Conference

In partnership with the International Association for the Study of Lung Cancer, the American Association for Cancer Research will host the AACR-IASLC Joint Conference on Molecular Origins of Lung Cancer, which will bring together leaders from all over the world who share the goal of eradicating this form of cancer.

15 Dec 2009

Trial date set for patent litigation in the U.S. District Court for the District of Delaware

Cubist Pharmaceuticals, Inc. today announced that a trial date has been set for patent litigation in the U.S. District Court for the District of Delaware against Teva Parenteral Medicines, Inc. (TPM), Teva Pharmaceuticals USA, Inc. and Teva Pharmaceutical Industries Ltd. alleging infringement of Cubist’s US Patent Nos. 6,468,967 and 6,852,689, which expire on September 24, 2019, and US Patent No. RE39,071, which expires on June 15, 2016.

14 Dec 2009

Cell-enriched breast reconstruction procedure improves breast deformity in lumpectomy patients

Interim results from a European clinical trial, RESTORE 2, demonstrate that cell-enriched breast reconstruction achieved a high rate of patient and physician satisfaction and improvements in overall breast deformity in lumpectomy patients.

14 Dec 2009

Results from Phase 2 trial evaluating Nexavar with capecitabine and paclitaxel presented

Bayer HealthCare Pharmaceuticals and Onyx Pharmaceuticals, Inc. today announced results from two collaborative group-sponsored randomized, double-blind, placebo-controlled Phase 2 trials were presented at the 32nd Annual San Antonio Breast Cancer Symposium (SABCS).

14 Dec 2009

Cubist Pharmaceuticals signs definitive agreement to acquire Calixa Therapeutics

Cubist Pharmaceuticals, Inc. a leading acute care therapeutics company, announced today the signing of a definitive agreement under which Cubist has agreed to acquire privately held Calixa Therapeutics Inc., a biopharmaceutical company focused on the development of novel antibiotics that address the expanding problem of multi-drug resistant Gram-negative pathogens.

14 Dec 2009

New Hill-Rom's Advanta 2 Bed for hospitals and home care facilities

Hill-Rom today announced the introduction of Hill-Rom's Advanta(TM) 2 Bed for use in medical-surgical areas of hospitals and care facilities. The new bed brings together ease of use with key safety features and the flexibility to use a variety of care surfaces as needed.

14 Dec 2009

Enrollment of patients for Phase IIb clinical trial of WBI-1001 commenced

Welichem today announced that the Company has begun to enroll patients in a Phase IIb clinical trial with its lead candidate, WBI-1001. The Phase IIb clinical trial is a double-blinded, placebo-controlled, 12-week-treatment study.

12 Dec 2009

Phase 2 pivotal trial of AC220 initiated by Ambit Biosciences

Ambit Biosciences Corporation announced today the enrollment and dosing at the University of Texas M. D. Anderson Cancer Center of the first patient in the ACE (AC220 Monotherapy Efficacy) Phase 2 pivotal trial in patients with relapsed or refractory acute myeloid leukemia (AML).

11 Dec 2009

Skin News and Research

DNA reveals earliest proven case of leprosy, Turin Shroud not from Jesus-era Jerusalem

StemCells receives U.S. patent for propagation and/or derivation of embryonic stem cells

MRSA, the most concerning pathogen to surveyed for skin and skin structure infections

ProtoKinetix evaluates major European proposals to expand AAGP technology use

Rib-X Pharmaceuticals and MGH enter into collaborative research agreement

BioAlliance Pharma SA to enter Phase II clinical trial for clonidine Lauriad and Phase I clinical trial for AMEP

FDA grants marketing approval for EnzySurge's new SilverStream solution for prescription use

Cellular and subcellular effects of PACE technology presented

Findings suggest variations in accelerated aging disorders

PPI announces new Exotec Cubital Tunnel Splint

INS cites FDA-approved Totect antidote for anthracycline extravasations

Majority of women take natural menopause remedies for safe and effective solutions

Health experts discuss new treatment strategies for lung cancer at AACR-IASLC Joint Conference

Trial date set for patent litigation in the U.S. District Court for the District of Delaware

Cell-enriched breast reconstruction procedure improves breast deformity in lumpectomy patients

Results from Phase 2 trial evaluating Nexavar with capecitabine and paclitaxel presented

Cubist Pharmaceuticals signs definitive agreement to acquire Calixa Therapeutics

New Hill-Rom's Advanta 2 Bed for hospitals and home care facilities

Enrollment of patients for Phase IIb clinical trial of WBI-1001 commenced

Phase 2 pivotal trial of AC220 initiated by Ambit Biosciences

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest News